GLP-1 Medications and Type 2 Diabetes Prevention: What the Latest Research Actually Shows

Type 2 diabetes is no longer a distant threat for most American men — it is a present reality. A landmark 2025 review in JAMA estimates that type 2 diabetes now affects approximately 1 in 6 adults in the United States, with global case counts ranging between 589 million and 828 million people. That is not a typo. Nearly a billion people worldwide are managing a condition that, left unchecked, progressively destroys the body’s ability to regulate blood sugar, damages the heart and kidneys, and shortens life expectancy. And yet much of this is preventable — and increasingly, treatable with a class of medications that are fundamentally changing the metabolic landscape.

Glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, have moved from niche diabetes drugs to some of the most studied medications in modern medicine. If you follow health news even casually, you have heard of semaglutide and liraglutide. But the conversation often gets hijacked by weight loss headlines, celebrity culture, or supply chain shortages. What gets lost is the harder, more important story: how these medications work against type 2 diabetes specifically, what the clinical trials actually demonstrate about cardiovascular and metabolic outcomes, and where lifestyle still carries more weight than any prescription.

What GLP-1 Medications Actually Do Inside the Body

To understand why GLP-1 receptor agonists are so effective in the context of type 2 diabetes, you need to understand the underlying physiology they are targeting. Type 2 diabetes is fundamentally a dual failure — progressive loss of insulin secretion from pancreatic beta cells layered on top of chronic insulin resistance. The body cannot produce enough insulin relative to demand, and the insulin it does produce is increasingly ignored by muscle, fat, and liver tissue. The result is sustained hyperglycemia, which acts like acid on blood vessels, nerves, and organs over time.

GLP-1 is a naturally occurring hormone released from the gut in response to food. It stimulates insulin secretion in a glucose-dependent manner — meaning it only triggers insulin release when blood sugar is actually elevated, which dramatically reduces the risk of hypoglycemia compared to older diabetes drugs like sulfonylureas. It also slows gastric emptying, reduces appetite signaling in the brain, and appears to have direct protective effects on beta cells themselves. GLP-1 receptor agonists are engineered versions of this hormone designed to resist rapid breakdown, giving them much longer active windows — ranging from hours with liraglutide to approximately one week with injectable semaglutide.

The 2025 JAMA review positions GLP-1 RAs and SGLT2 inhibitors as first-line therapy alongside metformin for patients with type 2 diabetes who also carry cardiovascular or kidney disease risk — a significant clinical evolution from even five years ago. High-potency GLP-1 RA and dual GIP/GLP-1 RA medications produce weight loss exceeding 5% in most individuals with type 2 diabetes, with some patients losing more than 10% of body weight. Since excess adiposity — particularly visceral fat — is one of the primary drivers of insulin resistance, this weight reduction amplifies the glucose-lowering effect well beyond what the drug alone would produce.

The Cardiovascular Evidence Is Hard to Ignore

Perhaps the most compelling argument for GLP-1 medications in the context of diabetes management is not their glucose-lowering capacity — it is their demonstrated ability to reduce the risk of dying from the complications that actually kill people with type 2 diabetes. Cardiovascular disease is present in approximately one-third of adults with type 2 diabetes, and it remains the leading cause of death in this population.

The LEADER trial, published in the New England Journal of Medicine in 2016, randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to either liraglutide or placebo for a median follow-up of 3.8 years. The results were striking: the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke occurred in 13.0% of the liraglutide group versus 14.9% in the placebo group. Death from cardiovascular causes was 4.7% in the liraglutide arm compared to 6.0% in placebo — a statistically significant reduction. All-cause mortality followed the same pattern, 8.2% versus 9.6%, favoring liraglutide.

The SUSTAIN-6 trial delivered comparable evidence for semaglutide. That study, also published in the New England Journal of Medicine, assigned 3,297 patients with type 2 diabetes to once-weekly semaglutide or placebo over 104 weeks. The primary cardiovascular outcome occurred in 6.6% of the semaglutide group versus 8.9% with placebo — a hazard ratio of 0.74. Nonfatal stroke was particularly reduced, dropping from 2.7% to 1.6%.

Most recently, the SOUL trial — published in 2025 in the New England Journal of Medicine — extended this evidence to oral semaglutide. In nearly 9,650 participants with type 2 diabetes and established atherosclerotic cardiovascular disease or chronic kidney disease, oral semaglutide (14 mg daily) reduced major adverse cardiovascular events by a hazard ratio of 0.86 compared to placebo over a median follow-up of nearly 50 months. The practical implication is significant: a once-daily pill now carries the same cardiovascular benefit data that once required an injection.

Even more unexpected was evidence published in early 2025 from the STRIDE trial. That Lancet-published study evaluated semaglutide 1.0 mg weekly in 792 patients with type 2 diabetes and symptomatic peripheral artery disease — a condition affecting over 230 million people globally that causes debilitating leg pain during walking. After 52 weeks, maximum walking distance improved significantly in the semaglutide group compared to placebo, with an estimated treatment ratio of 1.13. For men who cannot walk a city block without stopping due to arterial disease, a 13% improvement in functional capacity is not a minor quality-of-life footnote — it is the difference between independence and limitation.

Where Lifestyle Remains Non-Negotiable

None of the data above should be read as an argument that GLP-1 medications are a replacement for foundational health behaviors. The same JAMA review that highlights GLP-1 RAs so prominently also notes that physical activity alone can reduce hemoglobin A1C by 0.4% to 1.0% and improve both blood pressure and lipid profiles. Randomized clinical trials tracking intensive glucose-lowering strategies over two decades show absolute reductions in microvascular complications like retinopathy and nephropathy of 3.5%, myocardial infarction by 3.3% to 6.2%, and mortality by 2.7% to 4.9% — driven largely by consistent lifestyle and medication adherence combined.

Most of the men in these trials were also taking metformin — still the recommended first-line medication for most people newly diagnosed with type 2 diabetes, and one of the most cost-effective drugs in existence. GLP-1 medications are layered on top of this foundation, not substituted for it. And the lifestyle components — resistance training to improve insulin sensitivity in muscle tissue, a diet structured around protein and minimally processed foods, consistent sleep, and stress management — remain the bedrock that makes any pharmacological intervention work better and last longer.

For men who are prediabetic or at elevated risk based on the established factors — age over 45, family history, overweight or obese BMI, sedentary lifestyle, or prior gestational diabetes in a partner — the preventive window is wide open. GLP-1 receptor agonists are not yet widely approved specifically for diabetes prevention in the absence of a diagnosis, but the metabolic improvements they drive — reduced visceral fat, better insulin sensitivity, lower fasting glucose — are mechanistically protective.

What This Means For You

If you are managing type 2 diabetes, the clinical evidence for GLP-1 receptor agonists is now robust enough that a conversation with your physician about whether one fits your risk profile is entirely warranted — especially if you carry cardiovascular or kidney disease risk alongside your diabetes diagnosis. The data from LEADER, SUSTAIN-6, and SOUL is not preliminary or theoretical. It is large-scale, long-duration, placebo-controlled evidence showing real reductions in heart attacks, strokes, and mortality.

If you are not yet diabetic but recognize yourself in the risk profile, the most powerful intervention available to you remains deliberate: lift weights consistently, eat enough protein to support muscle mass, reduce ultra-processed food, and get your fasting glucose and A1C tested annually. Metabolic disease moves slowly and quietly until it does not. The window to act is now, and whether that action involves a prescription, a better training program, or both — the biology rewards the effort.